Why Halozyme Therapeutics (HALO) Is Drawing Investor Attention Now

Halozyme Therapeutics (HALO) is back on investors’ radar after a period of mixed share performance, with the stock roughly flat over the past month but lower over the past 3 months.

At around US$68.52, Halozyme’s recent share price moves have been relatively muted, yet the 1 year total shareholder return of 27.48% and 3 year total shareholder return of 106.76% point to longer term momentum that investors are weighing against more recent share price softness.

If Halozyme’s profile has you reconsidering where growth could come from next, it may be worth broadening your search to other healthcare focused AI opportunities via 33 healthcare AI stocks

With Halozyme trading at about US$68.52, revenue of US$1.51b and net income of US$348.84m, plus an analyst target of US$83.90, investors now have to ask whether there is genuine upside left or if the stock already reflects future growth.

Most Popular Narrative: 20.1% Undervalued

With Halozyme trading at $68.52 against a most followed fair value estimate of $85.78, the current price sits well below that narrative view.

The accelerating adoption of subcutaneous drug delivery in place of traditional intravenous administration, evidenced by rapid conversion rates (e.g., DARZALEX subcutaneous now 96% in the US) and label expansions (Phesgo for at-home administration), positions Halozyme's ENHANZE platform as a core beneficiary of the global shift towards more patient-friendly, convenient, and cost-effective treatment modalities. This structural shift is expected to support continued robust growth in royalty revenues and net margin expansion over the long term.

Curious what earnings trajectory and margin profile sit behind that fair value gap? The narrative focuses on richer royalties, rising profitability, and a future earnings multiple that looks far leaner than today.

Result: Fair Value of $85.78 (UNDERVALUED)

However, that story can change quickly if key partners slow subcutaneous adoption or if ongoing patent challenges weaken protection around the ENHANZE platform.

Another View: What The P/E Ratio Is Telling You

That 20.1% gap to the US$85.78 fair value estimate leans on long term earnings forecasts, but the current P/E of 23.3x paints a different picture. It sits higher than the US Biotechs industry at 16.2x and above a fair ratio of 17.7x, which points to less margin for error if forecasts do not play out as expected. Does that premium feel earned to you, or is it more optimism than evidence so far?

Next Steps

Mixed signals on value and risk can be confusing, so do not wait on someone else’s verdict. Weigh the data for yourself with 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If Halozyme has sharpened your thinking, do not stop here. Widen your watchlist now so you do not miss other compelling setups across the market.

• Hunt for potential mispricings by scanning 53 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
• Strengthen your income stream by reviewing 10 dividend fortresses built around higher yielding companies with resilient payout profiles.
• Prioritise resilience by assessing 66 resilient stocks with low risk scores designed for investors who want steadier companies with lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.